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Abstract
PartialEN(enteralnutrition)shouldalwaysbeaimedforinpatientswith
renalfailurethatrequirenutritionalsupport.NeverthelessPN(parenteral
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or chronic renal failure (ARF or CRF) and additional acute diseases but
without extracorporeal renal replacement therapy, or in patients with
ARF or CRF with additional acute diseases on extracorporeal renal re- guidelines for
placementtherapy,haemodialysistherapy(HD),peritonealdialysis(PD) parenteral nutrition of
or continuous renal replacement therapy (CRRT), or in patients on HD The German therapy with intradialytic PN. Patients with renal failure who show
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marked metabolic derangements and changes in nutritional require-
ments require the use of specifically adapted nutrient solutions. The
substrate requirements of acutely ill, non-hypercatabolic patients with
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HDhaveahigherriskofdevelopingmalnutrition.IntradialyticPN(IDPN)
should be used if causes of malnutrition cannot be eliminated and
otherinterventionsfail.IDPNshouldonlybecarriedoutwhenmodifiable
causes of malnutrition are excluded and enhanced oral (like i.e. add-
itional energy drinks) or enteral supply is unsuccessful or cannot be
carried out.
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Zusammenfassung
Patienten mit Nierenversagen sollten, wenn möglich, eine zumindest
partielle enterale Ernährung erhalten. Trotzdem kann bei bestimmten
PatientengruppenmitNierenversageneinePE(parenteraleErnährung)
notwendigwerden,wiez.B.beiPatientenmitakutembzw.chronischem
Nierenversagen(ANVbzw.CNV)undzusätzlichenakutenErkrankungen
ohneextrakorporalenNierenersatz,beiPatientenmitANVundPatienten
mit CNV und zusätzlichen akuten Erkrankungen unter extrakorporaler
Nierenersatztherapie,Hämodialysetherapie(HD),Peritonealdialyse(PD)
oder kontinuierlicher Nierenersatztherapie (CRRT) sowie bei Patienten
unter HD Therapie mit intradialytischer parenteraler Ernährung. Bei
Patienten mit Nierenversagen machen umfangreiche metabolische
StörungenundÄnderungendesNährstoffbedarfesdieVerwendungvon
spezifischadaptiertenNährlösungennotwendig.Beiakut-krankennicht-
hyperkatabolen Patienten mit CNV entspricht der Substratbedarf dem
der Patienten mit ANV ohne Nierenersatztherapie (die Verwertung der
zugeführtenNährstoffemusssorgfältigüberprüftwerden).BeiPatienten
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wird der Substratbedarf vom Schweregrad der Erkrankung, Art und
Dosis der extrakorporalen Nierenersatzverfahren, dem Ernährungszu-
stand,derGrunderkrankungundvonimKrankheitsverlaufauftretenden
Komplikationen bestimmt. Patienten unter einer HD haben ein hohes
Risiko, eine Mangelernährung auszubilden. Eine intradialytische PE
(IDPE) sollte nur dann durchgeführt werden, wenn „beseitigbare” Ursa-
chen einer Mangelernährung ausgeschlossen wurden und wenn eine
diätetische/orale (z.B. Trinknahrung) oder enterale Therapie nicht vor-
genommen werden kann bzw. nicht erfolgreich ist.
Schlüsselwörter:akutesNierenversagen,chronischesNierenversagen,
Hämodialysetherapie, Peritonealdialyse
Preliminary remark
Inpatientswithrenalfailure,enteralnutrition(EN)should
be the primary choice for nutrition therapy, and admin-
istered whenever possible (see also recommendations
by the German Society of Nutrition (DGEM) on enteral
nutrition [1]). However, patients with renal failure often
have limitations in enteral intake, and therefore, the ad-
ministration of a quantitatively sufficient EN becomes
impossible. Dysfunction of gastric and intestinal motility
is observed in patients even with moderately abnormal
renal function and often restricts the a amount of EN
tolerated. Therefore, in clinical practice many acutely ill
patients with renal failure require temporary and/or
supplementary parenteral nutrition (PN). Even if PN is
required, one should always aim for establishind at least
aminimalenteralnutritiontoenhanceintestinalintegrity
[1].
The nutritional status has a massive impact on the prog-
nosis of patients with renal failure [2]. In acutely ill pa-
tients, however, the degree of malnutrition is not the only
indication to start PN/EN, but also when the patient can
not be sufficiently orally/enterally nourished, and the
degree of severity of the underlying illness and the asso-
ciated catabolism [3].
Only few systematic studies have performed on paren-
terally fed patients with renal failure, and only very few
controlled studies with an acceptable study design have
beenpublished.Therefore,recommendationsforpractice
for this patient group only reach the level of an expert
opinion (C).
General recommendations for nutrition and nutritional
requirements of patients with renal diseases have been
published by the National Kidney Foundation (NKF) [4],
as well as by the European Society for Parenteral and
Enteral Nutrition (ESPEN) [5], [6].
Parenteralnutritioninpatientswith
renal failure
• At least partial EN should always be aimed for in pa-
tientswithrenalfailurethatrequirenutritionalsupport
(C).
PN may be necessary in renal failure in the following pa-
tient groups (C).
• Patients with acute or chronic renal failure (ARF or
CRF) and additional acute diseases but without ex-
tracorporeal renal replacement therapy.
• Patients with ARF or CRF with additional acute dis-
eases on extracorporeal renal replacement therapy,
haemodialysis therapy (HD), peritoneal dialysis (PD)
or continuous renal replacement therapy (CRRT).
• Patients on HD therapy with intradialytic PN.
Commentary
PN is administered almost solely to patients with acute
(ARF) or chronic renal failure (CRF), or those on chronic
renal replacement therapy (HD or PD), who also have
acute diseases. ARF or CRF is not a crucial factor for PN
administration in intensive care patients, but rather it is
important whether the patient requires extracorporeal
therapy [HD] or continuous renal replacement therapy
(CRRT), as well as the presence of hypercatabolism de-
pending on the severity of disease.
Aims of PN in patients with renal failure
PN in patients with renal failure aims at reduction of the
hypercatabolic state, and the prevention or elimination
of malnutrition and related functions, such as immun-
ology, wound healing, antioxidative potential, inflamma-
tion. While delaying the progress of CRF through protein
or phosphate restriction is the aim of chronic dietary
therapy, this is not the goal of short-term PN, which is
usually administered only in acute situations.
Metabolicsituationinpatientswith
renal failure
• Patientswithrenalfailurewhoshowmarkedmetabolic
derangementsandchangesinnutritionalrequirements
require the use of specifically adapted nutrient solu-
tions (C).
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Metabolism in patients with renal failure is not only influ-
enced by abnormal renal function, but also by the under-
lying disease, emerging complications and additional
organ failure (Table 1). Metabolism and nutrient balance
are also influenced by the type and intensity of extracor-
porealrenalreplacementtherapy[7].Distinctivechanges
inmetabolismandsubstraterequirementsofrenalfailure
patientsmakeitnecessarytoadaptPNaccordingtotheir
needs [7] (Table 1).
Table 1: Metabolic disorders in patients with renal failure
Energy metabolism is not markedly influenced by renal
dysfunctionbutmaybealteredbyunderlyingdiseaseand
accompanying complications. In multiple organ failure,
energy expenditure is only about 30% above the calcu-
lated resting metabolic rate [8]. An increase in energy
intake of more than 30 kcal/kg/day was not associated
with any further improvement in nitrogen balance, but
resulted in increased metabolic complications [9].
The metabolic changes in ARF are mainly characterised
byproteincatabolism.Therearealterationsofthemetab-
olism of individual amino acids, including the utilisation
of exogenously administered amino acids is altered, and
various non-essential amino acids, e.g. tyrosine, may
become indispensible.
Dysfunctions in carbohydrate metabolism in ARF usually
manifestclinicallythroughhyperglycaemia.Thisismainly
caused by peripheral insulin resistance, and in addition
by an activation of hepatic gluconeogenesis that cannot
be suppressed by exogenous nutrient intake, other than
in stable CRF and healthy persons (“obligatory” negative
nitrogen balance).
Altered lipid metabolism is characterised by hypertrigly-
ceridemia explained by the suppressed lipolysis. Fat
clearance is delayed after enteral or parenteral intake
[10].
PatientswithARForpatientswithCRFandacutediseases
have a markedly reduced antioxidative potential [11].
Activation of vitamin D3 is also impaired in ARF resulting
in secondary hyperparathyroidism [12].
Influence of renal replacement therapy
on metabolic and nutrient balances
Metabolic changes due to haemodialysis are shown in
Table 2. Currently continuous renal replacement therapy
(CRRT),especiallycontinuousvenovenoushaemofiltration
(CVVH), is usually used in intensive care patients. The
continuous therapy mode and the usually high filtration
rates result in significant influences on electrolyte and
nutrient balance, especially when losses are not suffi-
ciently replaced [13]. The loss of amino acids is approxi-
mately 0.2 g per litre of filtrate. Other substances such
as water-soluble vitamins are also lost. Complications
can also occur through excessive lactate or citrate intake
through the dialysate fluid (hyperlactaemia, metabolic
alkalosis).
Table 2: Effects of haemodialysis
Electrolyte metabolic disorders such as hypophos-
phataemia, hypomagnesaemia and/or hyponatraemia
are frequently observed due to the high fluid turnover
required for CRRT [13] (Table 3).
Table 3: Effects of continuous renal replacement therapy
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Amino acid solutions
• Special amino acid solutions for patients with renal
failure (so-called “nephro-solutions”) show beneficial
effects on some surrogate parameters, but effects on
clinical end points are not documented (IV).
• Solutions providing exclusively essential amino acids
should no longer be used (A).
Commentary
Renalfailureinfluencestheaminoacidorproteinmetab-
olism,andchangestheutilisationofintravenouslyadmin-
istered amino acids [14]. However, the question as to
which parenteral amino acid solution should be used in
these patients remains controversial. Potential advan-
tagesofspeciallyadaptedaminoacidsolutions(“nephro-
solutions”)includeassuredintakeofanadequate(higher)
dose of amino acids without urea increase, partial/total
correction of imbalances in plasma aminograms and the
intakeofaminoacidsthatbecomeessentialduetorenal
failure (i.e. tyrosine as dipeptide) [15], [16]. Previously
usedsolutionsprovidingexclusivelyessentialaminoacids
should not be used [7].
Clinicaladvantagessuchasimprovedsurvivalrateshave
not been documented with the use of “nephro-solutions”
(cf. chapter “Amino acids” http://www.egms.de/en/
gms/2009-7/000083.shtml). Benefits are most likely in
patients who do not require dialysis and whose urea in-
crease can be reduced. In patients who require renal re-
placement therapy, the advantages are expeceted to be
lessrelevantbecausehaemodialysisandhaemofiltration
have a “smoothing” effect on the plasma aminogram.
Therearenoadvantagesinusingsolutionsenrichedwith
branched-chainaminoacidsinintensivecarepatientsor
patients with ARF [17].
In 1982 Mirtallo et al. administered either a standard
amino acid solution (AA intake 33 g/day) or a solution
comprisedexclusivelyofessentialaminoacids(AAintake
29 g/day) to patients with non-dialysis CRF. Various
parameters in the nitrogen balance tended to a slight
improvement when the standard solution was used [18].
In a controlled study, Smolle et al. compared a conven-
tional amino acid solution with a “nephro-solution” in
patients with ARF [16]. The modified solution resulted in
anormalisationofplasmaaminoacidconcentrationsand
the phenylalanine/tyrosine ratio.
Lipid emulsions
• Patients with renal failure should receive lipid emul-
sions with a triglyceride dose of up to 1 g/kg body
weight/day in PN with regular montoring of plasma
triglycerides (C).
Commentary
The first step in lipid utilisation is the lipolysis of the in-
fused triglycerides which is reduced in renal failure, with
impairedfatclearanceinpatientswithARFandCRF[10].
Oxidationofthereleasedfattyacidsisnotimpaired.Lipid
emulsions can be used in PN but the dose should not
exceed ~1 g/kg body weight/day. Regular monitoring of
plasma triglycerides should be performed. At present
there are no studies documenting any advantages of
specific lipid emulsions over others in patients with renal
failure (cf. chapter “Lipid emulsions” http://www.egms.
de/en/gms/2009-7/000081.shtml).
Carbohydrates
• Parenteral carbohydrates should be provided by glu-
cose in patients with renal failure (C).
• NormoglycaemiashouldbethegoalduringPN.Insulin
isfrequentlyrequiredformaintainingnormoglycaemia
in these patients who often show insulin resistance
(A).
Commentary
Advantages of using parenteral glucose substitutes pa-
tientswithrenalfailurearenotshown,buttheirusemight
be associated with significant disadvantages. Glucose
substitutes are partly metabolised in the kidney and in-
crease renal oxygen consumption [19].
Normoglycaemia should be maintained in patients with
renal failure when using PN [20]. Insulin is frequently re-
quired to maintain normoglycaemia as these patients
often show insulin resistance.
L-carnitine
• The administration of L-carnitine (500 mg/day) is jus-
tified in malnourished and critically-ill patients on
renal replacement therapy (and thus increased loss)
(C).
Commentary
Whether L-carnitine should be regarded as an essential
substrate in patients with renal failure has not yet been
clarified.“Carnitineresponders”aremainlymalnourished
patients [4]. Good prospective studies and evidence-
based dosing specifications are not available.
Vitamins
Fat-soluble vitamins
• Patients with chronic renal failure require an individu-
ally dosed pharmacological therapy with vitamin D3
oritsanaloguesinadditiontothestandardintakewith
fat-soluble vitamins in PN (C).
4/11 GMS German Medical Science 2009, Vol. 7, ISSN 1612-3174
Druml et al.: Parenteral nutrition in patients with renal failure ...• Patients with CRF and acute concomitant diseases as
well as patients with ARF have an increased require-
ment of vitamin E (C).
Commentary
Patients with renal failure have dysfunctional activation
of vitamin D. For this reason activated vitamin D3 or its
analogues should be administered. The substitution of
vitamin K exceeding daily basal requirements is not ne-
cessary.IncontrasttostablepatientswithCRF,thelevels
of vitamin E and vitamin A are lower in acutely ill patients
with renal failure, which results in the need for substitu-
tion [12]. Systematic substitution studies are, however,
not available.
Water-soluble vitamins
• Patients on renal replacement therapy and malnour-
ished patients without renal replacement therapy
should receive approximately double the normal daily
requirements of water-soluble vitamins with PN (C).
• An increased intake of vitamin C (>250 mg/day) can
be disadvantageous and result in increased oxalate
formation (B).
Commentary
Patients with renal failure require an increased dose of
water-soluble vitamins. In patients on renal replacement
therapy, the dosage should amount to approximately
2-fold the daily requirements due to additional losses
through therapy [21], [22], [23].
The vitamin C supplementation should also be higher
than the recommended daily intake of healthy persons,
but should not exceed 250 mg/day, in order to prevent
possible secondary oxalosis. Excessive vitamin C in-
take/supplementation can even cause ARF itself [24].
Trace elements
• Patients on renal replacement therapy and malnour-
ished patients without renal replacement therapy
should receive the recommended daily intake of trace
elements in PN (C).
• Selenium intake should be >200 µg/day in patients
on renal replacement therapy (B).
Commentary
Renalbalancestudiesoftraceelementsarenotavailable
except for selenium, hence, in accordance with other
patient groups supplementation should correspond to
the recommended daily intake of healthy persons [3].
Selenium is an exception, as approximately double the
daily intake is lost through continuous renal therapy,
despite its high protein binding properties. Therefore, an
increased supplementation should be given [21] (B).
Electrolytes
• Electrolyte intake should be individually determined
in patients with renal failure (C).
Commentary
Potassium and phosphate restriction is generally recom-
mended in patients with renal failure. The requirements
are, however, extremely different for acutely ill patients.
Hypokalaemia or hypophosphataemia may occur initially
in the disease course. A fast decline in potassium or
phosphate levels may also occur in patients with renal
failure after commencing PN (“Refeeding hypophos-
phataemia or hypokalaemia”). The individual electrolyte
requirement can vary tremendously during the course of
disease and is crucially influenced by residual diuresis.
PN in patients with ARF/CRF
without renal replacement therapy
• The substrate requirements of acutely ill, non-hyper-
catabolic with CRF correspond to those of patients
with ARF who are not receiving any renal replacement
patients therapy (C) (Table 4).
• In patients with renal failure, PN should be started
slowly (approximately 50% of the requirements) in
order to monitor the utilisation of the administered
nutrients and prevent metabolic imbalances (C).
Commentary
PatientswithCRForARF,whodonotrequirerenalreplace-
ment therapy, are rarely catabolic, whereas dialysis is
necessaryinincreasedcatabolismduetotheassociated
increase of urea. Only a few of these patients require PN.
The substrate requirements of acutely ill, non-hypercata-
bolic patients with CRF correspond to those of patients
with ARF without renal replacement therapy (Table 4).
Renalfailurepatientswithuraemiadevelopmalnutrition,
related to the stage of the disease. The reasons for this
aremanifoldandcompriseloweroralfoodintake,restrict-
ivedietregime,thetoxiceffectsofuraemia,inflammation,
metabolic acidosis, endocrine factors such as insulin
resistance, hyperparathyroidism, altered leptin levels, as
well as gastroplegia, malassimilation and other
gastrointestinal alterations [25].
PN in patients with ARF/CRF and
renal replacement therapy
• In ARF patients and acutely ill CRF patients on renal
replacementtherapy,substraterequirementsdepend
on disease severity, type and extent/frequency of ex-
tracorporeal renal replacement therapy, nutritional
status,underlyingdiseaseandcomplicationsoccurring
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Table 5: Recommended parenteral substrate intakes in patients with ARF and in acutely ill patients on renal replacement
therapy
duringthecourseofthedisease(forrecommendations
for medium substrate intake see Table 5) (C).
Commentary
Critically ill patients with ARF are by far, the largest group
ofpatientswithrenalfailurewhorequireparenteralnutri-
tion therapy. ARF is rarely a mono-organ failure; usually,
additional complications like severe infections, sepsis or
multi-organ failure also occur. In these patients, ARF is
only one factor that determines the need for and type of
nutritional therapy (cf. chapter “Intensive medicine”,
http://www.egms.de/en/gms/2009-7/000073.shtml).
Altered water and electrolyte balance, specific metabolic
disorders, gastrointestinal motility and influence of ex-
tracorporeal therapies on metabolic and substrate bal-
ances should be considered during planning, execution
and monitoring of PN in renal failure patients.
Patients on intermittent haemodialysis therapy with ac-
companyingacutediseasesshouldbeassessedmetabol-
ically like patients with ARF, and treated similarly with
regards to nutritional therapy. The specifications made
hereforARFcan,therefore,beusedforboththesepatient
groups.
Indications for nutritional therapy
The same recommendations apply for PN therapy of pa-
tientswithARFasforotherintensivecarepatients.Nutri-
tional state is a significant determinant of outcome in
ARFpatients,smilartopatientswithotheracutediseases.
PN is indicated in patients with ARF without pre-existing
malnutrition who will not be able receive sufficient oral
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applies to ARF patients because underlying diseases
resulting in ARF tend to impair intestinal motility which
oftenlimitsquantitativelysufficiententeralnutrition[26].
In addition to duration of not meeting needs by oral or
enteralsupply,theextentofmalnutritionandtheseverity
of underlying diseases are main determinants of the in-
dication and timing for starting PN therapy.
Parenteral substrate requirements in
patients with ARF on renal replacement
therapy
• The requirement of amino acids/protein is increased
(A).
• Therequirementofwater-solublevitaminsisincreased
(A).
• The requirement of other micro nutrients (fat-soluble
vitamins, trace elements) should be met (A).
• Electrolyte intake should be dosed individually for pa-
tients with renal failure (C).
Commentary
The substrate requirements are determined less by
presence or absence of ARF, but more by the severity of
the disease, type and dose of the extracorporeal renal
replacementtherapy,underlyingdiseases,andcomplica-
tions occurring during the course of the disease. Toler-
ance to excessive substrate intakes (i.e. amino acids,
trace elements, vitamins) is reduced and overdoses
shouldthusbeavoidedbecausetheregulatoryfunctions
of the kidneys are missing in ARF.
(See section on “Influence of renal replacement therapy
on metabolism and nutrient balances” for vitamin and
trace element requirements.)
Amino acid requirements in patients
with ARF on renal replacement therapy
• The amino acid requirements of patients with ARF on
renal replacement therapy depend on the extent of
the underlying disease and the intensity of renal re-
placement therapy (B).
• Sufficient amino acid intake must be assured (B).
Commentary
The ideal amino acid intake in these patients is contro-
versial and has not been properly clarified through stud-
ies. There are no randomised studies with an adequate
study design.
There is, however, consensus that protein restriction,
which was previously recommended in analogy to CRF
with a minimal intake rate of approximately 0.6 g of AA/
kg/day, is not indicated in acutely ill patients.
Studies from the 1990s have dealt with the extent of
catabolism or the optimal intake. In numerous studies a
“proteincatabolicrate”of1.4to1.75g/kg/daywasfound
in patients with ARF under CRRT [17], [27], [28], [29]. In
these studies, a protein intake of this magnitude was
recommended which is consistent with the available in-
formation. Taking into account the amino acid loss
through CRRT of approximately 0.2 g/kg/day, this intake
is similar to the recommended intake of other intensive
care patients (cf. chapter “Intensive medicine” http://
www.egms.de/en/gms/2009-7/000073.shtml).
Recent studies from Australia [30], [31], [32] have sug-
gested that the amino acid/protein intake in intensive
care patients with ARF on CRRT should reach up to 2.5
g/kg/day. The authors found an increase in the plasma
amino acid levels and an enhanced nitrogen balance
which correlated with an improves outcome. The study
design, however, did not permit any conclusions on
causalityregardingimprovedoutcomesthroughincreased
amino acid intake.
Proteincatabolismcannotbesuppressedbyanincreased
amino acid intake in acute diseases. Potential dangers
of increased intake in patients with ARF are enhanced
uraemic toxicity and increased requirements of extracor-
poreal therapy. It unclear why patients with ARF should
have much higher amino acid requirements than other
intensive care patients, after adjustment of therapy-re-
lated loss.
AdmixtureofglutaminetoPNincritically
ill patients with ARF
• Glutamine intake should be avoided in non-dialysis
patients due to its high nitrogen content (C).
• In patients with ARF on renal replacement therapy,
glutamine intake may be considered (C).
Commentary
The question of whether glutamine should be added to
the PN solution in critically ill patients with ARF has not
been adequately answered. A post-hoc analysis of the
study of Griffith et al. has determined that the benefits
of glutamine supplementation were particularly marked
in patients with ARF on renal replacement therapy [33].
Theadministrationofglutamineshouldbecalculatedinto
theaminoacidintake,andthedoseofrenalreplacement
therapy adapted.
Metabolic monitoring in patients with
ARF
• Metabolic monitoring of nutritional therapy in ARF pa-
tients should be performed similar to monitoring in
other intensive care patients, but more stringently (C).
• In particular electrolyte balance must be checked
(frequent source of error!) (C).
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In patients with ARF there is a restricted tolerance to
volume intake and electrolytes, and impairment in the
metabolism of various substrates resulting in a high risk
of complications in nutrition therapy. More stringent
metabolic monitoring of nutrition therapy is, therefore,
necessary for this patient group as compared to other
patients.Slowintroductionofnutritionaltherapyreduces
the risk of occurrence of metabolic complications.
Influenceofparenteralnutritionon
the regeneration of renal function
Various nutrients can influence renal reparation and dif-
ferent aspects of renal function. Both parenterally and
enterally administered amino acids increase renal blood
flow as well as creatinine clearance (“renal reserve”).
However, amino acids have been found to be toxic for
the kidney.
There are three aspects to consider:
An unfavourable effect of AA on renal function and the
course of ARF (“AA paradox”) has been described in ani-
mal experiments [34]. This is only relevant when amino
acidsareinfusedinahigherdoseatthetimeoftheinsult,
thus increasing renal oxygen requirements, but appears
insignificant in the clinical situation. In contrast, it has
beenshownthatvariousaminoacidslikealanine,glycine,
taurineand,particularly,argininehaveaprotectiveeffect
onthekidneys,preventARFormaydelaytheprogression
of CRF [7]. The question as to what extent PN improves
renal reparation has not yet been determined. Abel et al.
suggested an improvement but this has not been con-
firmed in further studies [35]. However, experimentally
substrate deficiency aggravates renal damage in ARF.
Bothparenterallyandenterallyadministeredaminoacids
increase renal blood flow and also creatinine clearance
(“renal reserve”). An influence of this effect on renal
function in ARF has only been studied in animal experi-
ments[36],whereasclinicalobservationshaveonlybeen
reported in abstract form.
Intradialytic parenteral nutrition
(IDPN)
• Patients under haemodialysis (HD) have a higher risk
of developing malnutrition (A).
Commentary
The close connection between nutritional status and
complicationsoroutcomeiswelldocumentedforpatients
receiving chronic haemodialysis therapy. Malnutrition in
dialysispatientshasnumerouscauses;asignificantfactor
is anorexia leading to intakes below requirements [25],
[37].
Light to moderate malnutrition is found in approximately
30% of dialysis patients, and severe malnutrition in
5–10% [38]. Dietary interventions alone seem to have
only limited effect. Dialysis itself is a catabolic state
caused not only by losses of nutrients such as amino
acids, but also by activation of protein catabolism which
lasts for a few hours after the end of dialysis. Isotops
studies indicated that the catabolic state of HD can be
convertedtoananabolicstatethroughintradialyticnutri-
ent supply (Table 2) [39], [40].
Strategies for the treatment of
malnutrition in HD patients
Strategies for the treatment of malnutrition are summar-
ised in Table 6. In malnourished HD-patients with inad-
equate oral food intake, attempts can be made to motiv-
ate the patients to accept energy drinks during the HD
therapy which leads to an increased nutrient intake in
somepatients(seerecommendationin“EnteralNutrition
Guidelines” [1]). Intradialytic PN (IDPN) should be used
if causes of malnutrition cannot be eliminated and other
interventions fail.
Table 6: Malnutrition in HD patients – possibilities for
intervention
Indications for intradialytic PN
(IDPN)
• IDPN should only be carried out when modifiable
causes of malnutrition are excluded and enhanced
oral or enteral supply is unsuccessful or cannot be
carried out (C).
Commentary
The following international criteria for malnutrition have
been suggested, even though they are not based on firm
evidence [41]:
• Middle predialysis serum albumin 3 months
• Middle predialysis serum creatinine 3 months
• Weight loss >10% of ideal body weight or >20% of
normal body weight (no time limit)
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malnutrition
• Dietary history indicating protein intake <0.8 g/kg, re-
duced calorie intake <25 kcal/kg
• Subjective Global Assessment (SGA) “C”= severe
malnutrition
IDPN should be considered when three of the above
mentioned criteria are associated with the following
conditions:
• Aborted attempts to increase oral/enteral food intake
• Refusal of enteral gavage
Compounding and completion of IDPN
• The nutrient solution should be continuously infused
into the venous drip chamber of the tube system
throughout the complete duration of dialysis (B).
• Depending on the compounding of the nutrient solu-
tion,bloodglucose,triglyceridesandpossiblyeventhe
phosphate/potassium concentrations should be
checked during the first treatment (C).
Commentary
In many studies, only amino acid solutions have been
administered as IDPN, although some studies have in-
fused only slightly higher amounts than the 2 g/h loss
due to dialysis. Recent studies have coinfused amino
acids,glucoseandlipidstogetherwithpre-mixedsolutions
fromthepharmacyorcommercialready-madesolutions.
In some countries the concept of a complete nutrient
solution is practised, where water-soluble vitamins, car-
nitine and, if necessary, electrolytes are added to an all-
in-one bag containing the three basic nutrients of amino
acids/glucose/lipids. Preparation of a nutrient solution
on an individual basis, for every single patient, as occurs
in some countries, is extremely expensive and has no
documented advantages compared to standardised ad-
mixtures.
IDPN necessitates a compromise between the desire to
infuse an adequate amount of nutrients and a limited
time-frame in which these can be infused. The following
issues should be considered when deciding about the
infusion amount, even though evidence-based recom-
mendations are not available as of now (C).
Amino acids: Desirable intake >0.5 g/kg/dialysis.
“Nephro” solutions have been used in more recent stud-
ies [42].
Glucose:Limitsaresetduetotheshortinfusiontimeand
thefrequentlyexistingglucoseintolerance,recommended
intake 50–100 g/dialysis. Insulin must be given with
higher doses of glucose or to diabetics.
Lipids: Limitations exist due to dysfunction in lipolysis.
Anintakebetween20and40goflipids/dialysisappears
appropriate in order to prevent hypertriglyceridemia, in
contrast to higher dose recommendations by French
authors.
Double the usual daily dose of water-soluble vitamins
should be given, and in severely malnourished patients
carnitine should also be given.
The dialysis-related substrate loss is not considerably in-
creased by the infusion [43].
Studies on IDPN
Approximately 25 studies have been published on IDPN,
however,withverydifferentindications,nutrientsolutions
andnutrientinatkes,andlengthsoftherapy.Moststudies
were cohort studies without a control group; some were
retrospective and others used “run-in” periods prior to
the intervention. Only the study by Cano et al. was con-
trolled but did not include a placebo [44].
Almost all studies have shown significant improvements
in different parameters; including anthropometry (body
weight,midarmcircumference,tricepsskinfolds),serum
proteins,(albumin,totalprotein,transferrin,prealbumin),
plasmaaminoacidconcentrations,lymphocytecellsand
immune reactivity. An influence on survival was deter-
mined only in two studies, but firm conclusions cannot
bedrawnbecauseoflimitaionsinstudydesign[45],[46].
A multicenter study from France is currently being com-
pleted [47].
Abbreviations
ARF: acute renal failure
CAPD: chronic ambulant peritoneal dialysis
CRF: chronic compensated renal failure
CRRT: continuous renal replacement therapy
HD: chronic haemodialysis therapy
IDPN: intradialytic parenteral nutrition
MAC: mid-arm circumference
TSF: triceps skinfold
BW: body weight
PN: parenteral nutrition
Notes
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